MarketCap
Facebook
X
Telegram
Fate Therapeutics Income Statement 2025-2007 | FATE
Brief overview of financial performance at Fate Therapeutics
The conclusions below are based on five years of reported results. According to figures from Fate Therapeutics, revenue changed from 31.4 million dollars to 6.6 million dollars over five years. The five-year change reached −78.9%, while CAGR stood at −26.7%. The negative rate indicates weakening core operations.
Over the period, EBITDA shifted from −$125 million to −$135 million, a change of −7.8%. Operating profitability strengthened faster than the scale of sales. Comparing the endpoints gives EBITDA margins of −397.7% and −2028.3%. The business retained less EBITDA from each unit of revenue.
Across the five years, the net result shifted from −$173 million to −$136 million. The direction improved, yet positive earnings are still absent.
The market value of the business moved from 7.5 billion dollars to 187 million dollars, or −97.5%. The market is not yet fully reflecting the fundamental progress.
Summary assessment
Signs of deterioration dominate the five-year picture. The positive side is supported by net-income growth. The weaker side of the profile includes a softer top-line trend, pressure on operating profitability and a low EBITDA margin. Further direction will depend on top-line growth, operating profitability, and net income.
Annual Income Statement Fate Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
187 M | 102 M | 679 M | 595 M | 5.54 B | 7.49 B | 1.76 B | 829 M | 393 M | 88.3 M | 54.8 M | 104 M | 36.9 M | - | - | - | - | - | - |
Shares |
119 M | 114 M | 98.4 M | 96.8 M | 94.7 M | 82.4 M | 68.2 M | 56.2 M | 42 M | 31.8 M | 25.5 M | 20.5 M | 5.9 M | - | - | - | - | - | - |
Historical Prices |
1.57 | 0.9 | 6.9 | 6.14 | 58.5 | 90.9 | 19.6 | 12.8 | 6.11 | 2.51 | 3.37 | 5.03 | 6.28 | - | - | - | - | - | - |
Net Income |
-136 M | -186 M | -161 M | -282 M | -212 M | -173 M | -98.1 M | -66.6 M | -43 M | -33.5 M | -30 M | -25.9 M | -20.9 M | -14.2 M | -13.4 M | -16.2 M | -13.3 M | -7.17 M | -1.22 M |
Revenue |
6.65 M | 13.6 M | 63.5 M | 96.3 M | 55.8 M | 31.4 M | 10.7 M | 4.74 M | 4.11 M | 4.4 M | 2.43 M | - | 971 K | 2.67 M | 1.17 M | - | - | - | - |
Gross Profit |
- | - | - | - | - | - | - | - | - | - | 2.43 M | - | 971 K | 2.67 M | - | - | - | - | - |
Operating Income |
-148 M | -210 M | -191 M | -308 M | -217 M | -128 M | -101 M | -67.1 M | -42.1 M | -32 M | -27.8 M | -24.9 M | -17.7 M | -13.6 M | -13.3 M | - | - | - | - |
Interest Expense |
11.4 M | 24 M | 29.6 M | 26.7 M | 4.84 M | -45.3 M | 1.75 M | 1.7 M | 1.27 M | 1.64 M | 2.22 M | 549 K | 796 K | 487 K | 127 K | - | - | - | - |
EBITDA |
-135 M | -191 M | -172 M | -295 M | -211 M | -125 M | -98.5 M | -65.9 M | -41.2 M | -31.1 M | -27.1 M | -24.4 M | -17.1 M | -13 M | -12.6 M | - | - | - | - |
Operating Expenses |
154 M | 224 M | 254 M | 405 M | 273 M | 160 M | 111 M | 71.8 M | 46.2 M | 36.4 M | 30.2 M | 24.9 M | 18.6 M | 16.2 M | - | - | - | - | - |
General and Administrative Expenses |
46.5 M | 74.2 M | 2 M | 84.2 M | 57.3 M | 33.9 M | 23.6 M | 15.8 M | 11.9 M | 9.91 M | 10.4 M | 8.47 M | 6.64 M | 4.23 M | 4.6 M | - | - | - | - |
All numbers in USD currency
Quarterly Income Statement Fate Therapeutics
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
119 M | 120 M | - | 119 M | 119 M | 118 M | 114 M | 118 M | 117 M | 101 M | 98.6 M | 98.6 M | 98.4 M | 98.1 M | 97.3 M | 97 M | 96.7 M | 96.3 M | 95.7 M | 95.4 M | 94.3 M | 93.4 M | 87.7 M | 86.9 M | 79.3 M | 75.9 M | 75.7 M | 66.9 M | 65.2 M | 64.9 M | 64.7 M | 54.2 M | 53.1 M | 52.8 M | 52.6 M | 41.4 M | 41.4 M | 41.4 M | 41.4 M | 32.1 M | 28.9 M | 28.8 M | 28.7 M | 28.7 M | 23.9 M | 20.6 M | 20.6 M | 20.5 M | 20.5 M | 20.3 M | 20.4 M | 1.26 M | 1.24 M | 1.21 M | 1.33 M | 1.17 M | - | - | - | - | - | - |
Net Income |
-37.6 M | -31.2 M | - | -32.2 M | -34.1 M | -37.6 M | - | -47.7 M | -38.4 M | -48 M | - | -45.2 M | -52.8 M | -18.9 M | - | -83.6 M | -76.1 M | -65.7 M | - | -43.3 M | -55.1 M | -45.1 M | - | -58.7 M | -28.1 M | -33.5 M | -28.3 M | -26.6 M | -23.5 M | -19.8 M | -16 M | -16.8 M | -19.7 M | -14.1 M | -12.5 M | -10.7 M | -9.64 M | -10.1 M | -7.94 M | -8.74 M | -8.41 M | -8.38 M | -7.45 M | -6.89 M | -7.78 M | -7.88 M | -6.23 M | -6.6 M | -6.07 M | -6.98 M | -5.74 M | -6.07 M | -5.53 M | -3.55 M | -4.16 M | -4.11 M | -2.74 M | -3.23 M | - | - | - | - |
Revenue |
1.91 M | 1.3 M | - | 1.74 M | 1.91 M | 1.63 M | - | 3.07 M | 6.77 M | 1.92 M | - | 1.94 M | 933 K | 59 M | - | 15 M | 18.5 M | 18.4 M | - | 14.2 M | 13.4 M | 11.1 M | - | 7.56 M | 5.46 M | 2.52 M | 2.8 M | 2.43 M | 2.82 M | 2.63 M | 1.66 M | 1.03 M | 1.03 M | 1.03 M | 1.03 M | 1.03 M | 1.03 M | 1.03 M | 1.03 M | 1.03 M | 1.03 M | 1.32 M | 1.08 M | 1.03 M | 329 K | - | - | - | - | - | - | 209 K | 290 K | 472 K | 643 K | 528 K | 1.08 M | 418 K | - | - | - | - |
Operating Income |
-37 M | -33 M | - | -34.7 M | -37 M | -41.3 M | - | -52.4 M | -45.1 M | -51.1 M | - | -51.3 M | -62.6 M | -28.6 M | - | -86.4 M | -83.1 M | -74.5 M | - | -54.6 M | -46.8 M | -46.2 M | - | -31.5 M | -28.7 M | -34.5 M | - | -27.1 M | -24.1 M | -20.4 M | - | -16.7 M | -19.6 M | -14.1 M | - | -10.3 M | -9.57 M | -9.97 M | - | -8.39 M | -8 M | -7.92 M | - | -6.33 M | -7.22 M | -7.32 M | - | -5.98 M | -6.04 M | -6.94 M | - | -5.15 M | -4.27 M | -3.36 M | - | -3.65 M | - | - | - | - | - | - |
Interest Expense |
2.9 M | 1.79 M | - | 2.48 M | 2.9 M | 3.66 M | - | 4.7 M | 6.66 M | 3.06 M | - | 6.11 M | 9.81 M | 9.71 M | - | 2.83 M | 7 M | 8.78 M | - | 11.3 M | -8.35 M | 1.12 M | - | -27.2 M | 635 K | 972 K | - | 400 K | 409 K | 405 K | - | 429 K | 425 K | 412 K | - | 378 K | 212 K | 266 K | - | 385 K | 435 K | 488 K | - | 562 K | 563 K | 558 K | - | 187 K | 28 K | 43 K | - | 230 K | 88 K | 100 K | - | -463 K | - | - | - | - | - | - |
EBITDA |
-37 M | -30.1 M | - | - | - | -37.9 M | - | - | - | -46.2 M | - | - | - | -24.4 M | - | -77.5 M | -83.1 M | -71.7 M | - | -51 M | -46.8 M | -45.3 M | - | -29.3 M | -27.3 M | -33.8 M | - | -25.5 M | -23.1 M | -20 M | - | -15.8 M | -19 M | -13.8 M | - | -9.66 M | -9.13 M | -9.76 M | - | -7.71 M | -7.54 M | -7.69 M | - | -5.85 M | -6.93 M | -7.2 M | - | -5.61 M | -5.78 M | -6.81 M | - | -4.71 M | -3.97 M | -3.2 M | - | -3.22 M | - | - | - | - | - | - |
Operating Expenses |
38.9 M | 34.3 M | - | 36.5 M | 38.9 M | 42.9 M | - | 55.5 M | 51.9 M | 53 M | - | 53.2 M | 63.5 M | 87.6 M | - | 101 M | 102 M | 92.9 M | - | 68.8 M | 60.2 M | 57.4 M | - | 39 M | 34.2 M | 37 M | 31.9 M | 29.5 M | 26.9 M | 23.1 M | 18.4 M | 17.7 M | 20.6 M | 15.1 M | 13.3 M | 11.4 M | 10.6 M | 11 M | 8.68 M | 9.42 M | 9.03 M | 9.24 M | 7.99 M | 7.35 M | 7.55 M | 7.32 M | 5.94 M | 5.98 M | 6.04 M | 6.94 M | 4.9 M | 5.36 M | 4.56 M | 3.83 M | 4.69 M | 4.18 M | 3.82 M | 3.54 M | - | - | - | - |
General and Administrative Expenses |
11.4 M | 9.6 M | - | 10.6 M | 11.4 M | 13.8 M | - | 20.8 M | 17.3 M | 20.9 M | - | 18.9 M | 22.6 M | 2 M | - | 21.6 M | 20.4 M | 20.7 M | - | 15.7 M | 12.2 M | 12.5 M | - | 8.35 M | 7.5 M | 7.73 M | - | 6.35 M | 5.27 M | 5.35 M | - | 4.08 M | 3.82 M | 3.6 M | - | 2.79 M | 2.67 M | 3.03 M | - | 2.61 M | 2.25 M | 2.6 M | - | 2.35 M | 2.69 M | 2.76 M | - | 1.9 M | 2.07 M | 2.42 M | - | 1.98 M | 1.49 M | 1.3 M | - | 863 K | - | - | - | - | - | - |
All numbers in USD currency
The income statement is one of the three key financial reports of a company Fate Therapeutics (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
USA
Canada
China
Britain
France
Israel
Germany
Russia
Belgium
Cayman-islands
